The estimated Net Worth of Robert Crane is at least $180 Tausend dollars as of 16 March 2022. Robert Crane owns over 39,267 units of Axcella Health Inc stock worth over $179,843 and over the last 3 years Robert sold AXLA stock worth over $0.
Robert has made over 1 trades of the Axcella Health Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Robert bought 39,267 units of AXLA stock worth $75,000 on 16 March 2022.
The largest trade Robert's ever made was buying 39,267 units of Axcella Health Inc stock on 16 March 2022 worth over $75,000. On average, Robert trades about 19,634 units every 0 days since 2022. As of 16 March 2022 Robert still owns at least 39,267 units of Axcella Health Inc stock.
You can see the complete history of Robert Crane stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 5 years, insiders at Axcella Health Inc have traded over $32,393 worth of Axcella Health Inc stock and bought 29,966,648 units worth $79,278,835 . The most active insiders traders include Ventures Fund Iv General Pa..., Ventures Fund Iv General Pa... und Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of $3,073,698. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth $394.
axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.
Axcella Health Inc executives and other stock owners filed with the SEC include: